{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:44:39Z","timestamp":1777016679259,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"DOI":"10.7759\/cureus.107628","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:13:26Z","timestamp":1777014806000},"source":"Crossref","is-referenced-by-count":0,"title":["Sequential Acinetobacter lwoffii Bacteremia and Early Carbapenem-Resistant Acinetobacter baumannii Pneumonia in Diabetic Ketoacidosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Anu","family":"Prasad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong D","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017, 30:409-47. 10.1128\/CMR.00058-16","journal-title":"Clin Microbiol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg AY","year":"2008","unstructured":"Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008, 21:538-82. 10.1128\/CMR.00058-07","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn L","year":"2007","unstructured":"Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007, 5:939-51. 10.1038\/nrmicro1789","journal-title":"Nat Rev Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01601","article-title":"The mechanisms of disease caused by Acinetobacter baumannii","volume":"10","author":"Morris FC","year":"2019","unstructured":"Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The mechanisms of disease caused by Acinetobacter baumannii. Front Microbiol. 2019, 10:1601. 10.3389\/fmicb.2019.01601","journal-title":"Front Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00279-24","article-title":"Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen","volume":"38","author":"Dubey V","year":"2025","unstructured":"Dubey V, Reza N, Hope W. Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. Clin Microbiol Rev. 2025, 38:e0027924. 10.1128\/cmr.00279-24","journal-title":"Clin Microbiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s100960000315","article-title":"Clinical and microbiological characteristics of bacteremia caused by Acinetobacter lwoffii","volume":"19","author":"Ku SC","year":"2000","unstructured":"Ku SC, Hsueh PR, Yang PC, Luh KT. Clinical and microbiological characteristics of bacteremia caused by Acinetobacter lwoffii. Eur J Clin Microbiol Infect Dis. 2000, 19:501-5. 10.1007\/s100960000315","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/18256.7943","article-title":"Pyogenic liver abscess caused by Acinetobacter lwoffii: a case report","volume":"10","author":"Singh NP","year":"2016","unstructured":"Singh NP, Sagar T, Nirmal K, Kaur IR. Pyogenic liver abscess caused by Acinetobacter lwoffii: a case report. J Clin Diagn Res. 2016, 10:DD01-2. 10.7860\/JCDR\/2016\/18256.7943","journal-title":"J Clin Diagn Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.97617","article-title":"Acinetobacter lwoffii cellulitis in an immunocompromised patient with decompensated cirrhosis, diabetes mellitus, and psoriasis vulgaris: a case report","volume":"17","author":"Sakakiyama M","year":"2025","unstructured":"Sakakiyama M, Hayashi K, Matsuda H, Hayashi M. Acinetobacter lwoffii cellulitis in an immunocompromised patient with decompensated cirrhosis, diabetes mellitus, and psoriasis vulgaris: a case report. Cureus. 2025, 17:e97617. 10.7759\/cureus.97617","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678771","article-title":"A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity","volume":"12","author":"Dowey R","year":"2021","unstructured":"Dowey R, Iqbal A, Heller SR, Sabroe I, Prince LR. A bittersweet response to infection in diabetes; targeting neutrophils to modify inflammation and improve host immunity. Front Immunol. 2021, 12:678771. 10.3389\/fimmu.2021.678771","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_478_19","article-title":"Management of diabetic ketoacidosis in adults: a narrative review","volume":"8","author":"Eledrisi MS","year":"2020","unstructured":"Eledrisi MS, Elzouki AN. Management of diabetic ketoacidosis in adults: a narrative review. Saudi J Med Med Sci. 2020, 8:165-73. 10.4103\/sjmms.sjmms_478_19","journal-title":"Saudi J Med Med Sci"},{"key":"ref11","article-title":"Alcohol and the immune system","volume":"37","author":"Sarkar D","year":"2015","unstructured":"Sarkar D, Jung MK, Wang HJ. Alcohol and the immune system. Alcohol Res. 2015, 37:153-5.","journal-title":"Alcohol Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv133.1330","article-title":"Clinical and microbiological characteristics of Acinetobacter lwoffii bacteremia compared with Acinetobacter baumannii","volume":"2","author":"Rosa R","year":"2015","unstructured":"Rosa R, Mills J, Munoz Price LS. Clinical and microbiological characteristics of Acinetobacter lwoffii bacteremia compared with Acinetobacter baumannii. Open Forum Infect Dis. 2015, 2:1780. 10.1093\/ofid\/ofv133.1330","journal-title":"Open Forum Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.014","article-title":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","volume":"25","author":"Piperaki ET","year":"2019","unstructured":"Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019, 25:951-7. 10.1016\/j.cmi.2019.03.014","journal-title":"Clin Microbiol Infect"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya KK","year":"2020","unstructured":"Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020, 6:40. 10.1038\/s41572-020-0165-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05239-w","article-title":"Clinical features, antimicrobial susceptibilities, treatment characteristics and outcomes of paediatric Acinetobacter lwoffii bacteremia: a case series","volume":"44","author":"G\u00fcne\u015f \u00d6","year":"2025","unstructured":"G\u00fcne\u015f \u00d6, \u00d6zkaya-Parlakay A, G\u00fcney AY. Clinical features, antimicrobial susceptibilities, treatment characteristics and outcomes of paediatric Acinetobacter lwoffii bacteremia: a case series. Eur J Clin Microbiol Infect Dis. 2025, 44:2539-48. 10.1007\/s10096-025-05239-w","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00676-6","article-title":"Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis","volume":"10","author":"Blanchard F","year":"2020","unstructured":"Blanchard F, Charbit J, Van der Meersch G, et al.. Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis. Ann Intensive Care. 2020, 10:58. 10.1186\/s13613-020-00676-6","journal-title":"Ann Intensive Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318261","article-title":"Identification of early predictors and model for bacterial infection in diabetic ketoacidosis patients: a retrospective study","volume":"20","author":"Hao Y","year":"2025","unstructured":"Hao Y, Yang L, Meng X, Tang Y, Wang L. Identification of early predictors and model for bacterial infection in diabetic ketoacidosis patients: a retrospective study. PLoS One. 2025, 20:e0318261. 10.1371\/journal.pone.0318261","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","volume":"4","author":"Tamma PD","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024, 4:8-9. 10.1093\/cid\/ciae403","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye KS","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al.. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023, 23:1072-84. 10.1016\/S1473-3099(23)00184-6","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02319-16","article-title":"Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?","volume":"61","author":"Zavascki AP","year":"2017","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B?. Antimicrob Agents Chemother. 2017, 61:8-9. 10.1128\/AAC.02319-16","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478707-sequential-acinetobacter-lwoffii-bacteremia-and-early-carbapenem-resistant-acinetobacter-baumannii-pneumonia-in-diabetic-ketoacidosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:13:27Z","timestamp":1777014807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478707-sequential-acinetobacter-lwoffii-bacteremia-and-early-carbapenem-resistant-acinetobacter-baumannii-pneumonia-in-diabetic-ketoacidosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.107628","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}